Product ID |
Product Name |
CAS# |
Purity |
Y1247048 |
CC0651 |
1319207-44-7 |
99% |
Y1251359 |
CCT 241533 hydrochloride |
1431697-96-9 |
99% |
Y3297711 |
CDK9 inhibitor |
1415559-43-1 |
95% |
Y1246958 |
N2'-((1r,4r)-4-aMinocyclohexyl)-5'-chloro-N6-(3-fluorobenzyl)-[2,4'-bipyridine]-2',6-diaMine-rel- |
1263369-28-3 |
99% |
D762520 |
c-Met inhibitor 1 |
1357072-61-7 |
98+% |
D762053 |
CP 809101 hydrochloride |
1215721-40-6 |
98+% |
Y1343760 |
CX 6258 hydrochloride hydrate |
1353858-99-7 |
99% |
D762182 |
Cyclohexaneacetic acid, 4-(4-hydroxyphenyl)-, Methyl ester, cis- |
1245708-07-9 |
98% |
D762132 |
di-tert-butyl 2-Methyl-2-(5-(tosyloxy)pentyl)Malonate |
1236354-13-4 |
98% |
Y3131119 |
dofequidar |
129716-58-1 |
95% |
Y1246959 |
Doxercalciferol-D3 |
1217448-46-8 |
95% |
D962562 |
D-Proline, 3-(3-chloro-2-fluorophenyl)-4-(4-chloro-2-fluorophenyl)-4-cyano-5-(2,2-diMethylpropyl)-, 1,1-diMethylethyl ester, (3S,4R,5S)-rel- |
1219086-88-0 |
97% |
Y1242846 |
4-(4-fluorophenyl)-N-(3-Methoxy-4-(4-Methyl-1H-iMidazol-1-yl)phenyl)-4,5,6,7-tetrahydrobenzo[d]thiazol-2-aMine |
1431697-84-5 |
99% |
D752036 |
Gatifloxacinacid |
121577-32-0 |
98+% |
Y1242763 |
Glucocorticoid receptor agonist |
1245526-82-2 |
99% |
Y1238311 |
GNF179 Metabolite |
1310455-86-7 |
95% |
Y1242743 |
Hoechst 33258 analog 6 |
129244-66-2 |
98% |
Y3106370 |
Meta-Hoechst |
132869-83-1 |
98% |
Y1047919 |
IMidazo[1,2-d][1,4]benzoxazepine, 9-broMo-5,6-dihydro-2-[3-Methyl-1-(1-Methylethyl)-1H-1,2,4-triazol-5-yl]- |
1282514-63-9 |
98% |
Y1242834 |
INCB3344 |
1262238-11-8 |
99% |
Y1242869 |
3-[(1S,2S)-2-Hydroxycyclohexyl]-6-[(6-methyl-3-pyridinyl)methyl]benzo[h]quinazolin-4(3H)-one |
1227923-29-6 |
95% |
Y1242801 |
(5Z,7E,22E)-9,10-Seco-26,27-cyclo-1a,3ß-dihydroxycholesta-5,7,10(19),22-tetren-24-one |
126860-83-1 |
91% |
Y1247202 |
McMMAD |
1401963-15-2 |
98% |
D770457 |
Methyl 1-(4-broMophenyl)-3-hydroxycyclobutanecarboxylate |
1432059-59-0 |
98% |
Y3141243 |
MK8245 Trifluoroacetate |
1415559-41-9 |
95% |
Y1242764 |
MMAF (Hydrochloride) |
1415246-68-2 |
99% |
Y1337555 |
N-(2,3-Dichlorobenzyl)cyclopropanamine hydrochloride |
1260763-07-2 |
98% |
Y1242870 |
N-(3-Azidopropyl)-4-(2,6-di-tert-butyl-4-(6-(4-Methylpiperazin-1-yl)-1H-benzo[d]iMidazol-2-yl)phenoxy)butanaMide |
1311982-88-3 |
98% |
Y3252150 |
ON 146040 |
1404231-34-0 |
98% |
D762662 |
Oxazole, 5-broMo-2-(2-Methylphenyl)- |
1391739-99-3 |
97% |
Y1047921 |
pf-5274857 |
1373615-35-0 |
98+% |
Y3297721 |
PF-543 (Citrate) |
1415562-83-2 |
99% |
Y1242854 |
SB408124 Hydrochloride |
1431697-90-3 |
98% |
Y1251545 |
Seocalcitol |
134404-52-7 |
99% |
D963939 |
Spiro[3H-indole-3,3'-pyrrolidine]-5'-carboxaMide, 6-chloro-4'-(3-chloro-2-fluorophenyl)-2'-(2,2-diMethylpropyl)-1,2-dihydro-N-(trans-4-hydroxycyclohexyl)-1'-[(1R,2S)-2-hydroxy-1,2-diphenylethyl]-2-oxo-, (2'R,3S,4'S,5'R)- |
1303609-36-0 |
98% |
D770460 |
tert-butyl 7-benzyl-1,7-diazaspiro[4.5]decane-1-carboxylate oxalate |
1415560-12-1 |
97% |
Y1242855 |
TRPC6 inhibitor |
1333207-63-8 |
95% |
D770461 |
Urea, N,N'-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]- |
1365267-35-1 |
95+% |
D762603 |
Uridine, 4'-C-azido-, 2',3',5'-tribenzoate |
1365255-42-0 |
97% |
Y1247218 |
VTP-27999 (Hydrochloride) |
1264191-73-2 |
98% |
Y1047923 |
XL-388 |
1251156-08-7 |
98+% |
Y3288911 |
BID |
1416258-16-6 |
98% |
D770465 |
(S)-2-(6-hydroxy-2,3-dihydrobenzofuran-3-yl)acetic acid |
1380792-92-6 |
97% |
D762899 |
4-(4-methoxybenzoyl)-1-Piperidineacetic acid |
1419957-49-5 |
98% |
Y1054548 |
2-Hexenoic acid, 2-(acetylamino)-5-(2,3-difluorophenyl)-6-nitro-, compd. with N,N-dibutyl-1-butanamine (1 |
1254841-06-9 |
97% |
D964411 |
3(2H)-Isoquinolinone, 1-(4-chlorophenyl)-1,4-dihydro-6-methoxy-7-(1-methylethoxy)-2-[4-[methyl[[trans-4-(4-methyl-3-oxo-1-piperazinyl)cyclohexyl]methyl]amino]phenyl]- |
1313363-86-8 |
98% |
D964197 |
3-Benzofuranacetic acid, 6-[[2',6'-dimethyl-4'-[3-(methylsulfonyl)propoxy][1,1'-biphenyl]-3-yl]methoxy]-2,3-dihydro-, (3R)- |
1234474-57-7 |
95+% |
D770468 |
3-Quinolineethanol, 6-bromo-2-methoxy-a-1-naphthalenyl-ß-phenyl-, (ßR)- |
1298044-24-2 |
97% |
D962628 |
5-bromo-N-butyl-7-((1r,4r)-4-((tert-butyldimethylsilyl)oxy)cyclohexyl)-7H-pyrrolo[2,3-d]pyrimidin-2-amine |
1429882-29-0 |
98% |
Y1247190 |
6-Bromo-8-ethyl-2-[[4-(4-methylpiperazin-1-yl)phenyl]amino]-8H-pyrido[2,3-d]pyrimidin-7-one |
1232030-40-8 |
98% |
D770469 |
N'-acetyl-2-broMoacetohydrazide |
1342263-70-0 |
95+% |
D770470 |
Benzenamine, 3-methyl-4-(4-piperidinyl)- |
1260864-79-6 |
95+% |
D963620 |
Benzoic acid, 4-[[bis[(1,1-dimethylethoxy)carbonyl]amino][[(1,1- dimethylethoxy)carbonyl]imino]methyl]-, methyl ester |
135321-85-6 |
98% |
D958564 |
Benzonitrile, 4-bromo-2-fluoro-6-methyl- |
1427438-75-2 |
95+% |
D770472 |
Carbamic acid, N-[[4-[chloro(hydroxyimino)methyl]phenyl]methyl]-N-methyl-, 1,1-dimethylethyl ester |
1428935-49-2 |
98% |
D770473 |
tert-butyl (1-((trimethylsilyl)ethynyl)cyclopropyl)carbamate |
1268810-08-7 |
98% |
Y3246332 |
ChlorproMazine-d6 Hydrochloride |
1228182-46-4 |
99% |
Y3106269 |
E6446 (dihydrochloride) |
1345675-25-3 |
98% |
Y1247192 |
ENALAPRILAT-D5, SODIUM SALT |
1356922-29-6 |
98% |
Y1255885 |
GLPG0492 (R enantiomer) |
1215085-93-0 |
99% |
Y1251518 |
GSK-5498A |
1253186-49-0 |
98% |
Y1255887 |
Hydroxy Iloperidone |
133454-55-4 |
99% |
Y1255925 |
IRBESARTAN-D4 |
1216883-23-6 |
99% |
Y1343701 |
N-DeMethyl Ivabradine Hydrochloride |
1246638-08-3 |
98% |
Y3310928 |
KHK-IN-1 |
1303469-70-6 |
98% |
Y1339642 |
sodium 6-(2,6-dimethoxybenzamido)penicillanate |
132-92-3 |
85% |
Y1264683 |
Mirk-IN-1 |
1386979-55-0 |
99% |
Y1255907 |
Mutant IDH1-IN-2 |
1429176-69-1 |
98% |
D770475 |
Pentanoic acid, 2-bromo-4-methyl-, 1,1-dimethylethyl ester, (R)- |
130464-88-9 |
97% |
Y3140681 |
Piribedil-d8 |
1398044-45-5 |
97% |
Y3243632 |
Propafenone (D7 hydrochloride) |
1219799-06-0 |
98% |
Y3140695 |
PSI-6206 13CD3 |
1256490-42-2 |
99% |
Y1255909 |
S1P1 Agonist III |
1324003-64-6 |
98% |
D963409 |
Spiro[isobenzofuran-1(3H),9'-[9H]xanthene]-6-carboxylic acid, 3'-hydroxy-3-oxo-6'-[[(trifluoromethyl)sulfonyl]oxy]- |
1268491-68-4 |
97% |
Y1255948 |
Tetrabenazine-d6 |
1392826-25-3 |
98% |
Y1260376 |
ZK200775 (hydrate) |
1255517-78-2 |
99% |
D770476 |
(R)-2-((tert-butyldimethylsilyl)oxy)-1-(4-chloro-3-fluorophenyl)ethanol |
1395078-43-9 |
98% |
D770477 |
2-Propen-1-one, 1-[2-methoxy-6-[(4-methoxyphenyl)methoxy]phenyl]-3,3-bis(methylthio)- |
1234015-62-3 |
95% |
Y1260378 |
NS-018 |
1239358-86-1 |
99% |
Y1260379 |
NS-018 (hydrochloride) |
1239358-85-0 |
98% |
Y1260288 |
tert-butyl 2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylate |
1240893-76-8 |
98% |
D770479 |
3,3-Dimethyl-4-nitrobutanoic acid ethyl ester |
130912-54-8 |
95+% |
Y3141427 |
3-oxa-7-azabicyclo[3.3.1]nonan-9-ol |
1246187-79-0 |
95% |
Y1264685 |
1H-1,2,3-Triazole-1-acetic acid, 4-[[bis[[1-(1,1-diMethylethyl)-1H-1,2,3-triazol-4-yl]Methyl]aMino]Methyl]- |
1334179-85-9 |
99% |
Y3141254 |
Ethyl 3-(3-oxocyclobutyl)propanoate |
1380290-31-2 |
95% |
Y1247163 |
FMoc-Val-Cit-PAB-MMAE |
1350456-56-2 |
95% |
Y1238308 |
N-(3,3-difluorocyclobutyl)formamide |
1355328-30-1 |
98% |
Y1314452 |
(S)-2-(3'-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4'-bipyridin]-2'-yl)-7,7-dimethyl-3,4,7,8-tetrahydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one |
1434048-34-6 |
98% |
D964741 |
(4aR,4bS,6aS,7S,9aS,9bS,11aS)-4a,6a-diMethyl-2-oxohexadecahydro-1H-indeno[5,4-f]quinoline-7-carboxylic acid |
1430804-94-6 |
98% |
D964391 |
(E)-5-benzyl-7-(hydroxyimino)-5-azaspiro[2.4]heptan-4-one |
129306-06-5 |
98% |
D770482 |
8-Isoquinolinecarboxamide, N-2-benzothiazolyl-1,2,3,4-tetrahydro-, Dihydrochloride |
1235034-72-6 |
97% |
Y1054683 |
Butanedioic acid, 2,3-bis(benzoyloxy)-, (2R,3R)-, compd. with (11bR)-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isoquinolin-4-one (1 |
1399880-37-5 |
98% |
D958566 |
EthaniMidaMide, N-(4-broMo-2,6-difluorophenyl)-N'-(1-Methylethyl)- |
1231930-29-2 |
97% |
Y1238299 |
GNF-6231 |
1243245-18-2 |
98% |
Y3263817 |
L-Proline,4-[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-(phenylmethyl)-,methyl ester,(4S)- |
1318129-60-0 |
95% |
Y1238310 |
N 563 |
140686-92-6 |
98% |
D958567 |
(E)-N-(4-(N-(3-Methoxypyrazin-2-yl)sulfaMoyl)phenyl)-3-(5-nitrothiophen-2-yl)acrylaMide |
1360614-48-7 |
98+% |
Y1376907 |
BNP-32 (HUMAN) |
124584-08-3 |
98% |
Y3140709 |
R 80123 |
133718-30-6 |
98% |
Y1238264 |
Revizinone |
133718-29-3 |
98% |